» Articles » PMID: 25117730

Defined Serum- and Xeno-free Cryopreservation of Mesenchymal Stem Cells

Overview
Date 2014 Aug 14
PMID 25117730
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) have vast potential in cell therapy, and are experimentally used in the clinic. Therefore, it is critical to find a serum- and xeno-free cryopreservation method. The aim of this study was to compare two serum- and xeno-free cryoprotectants for MSCs. Adipose tissue MSCs (Ad-MSCs) and bone marrow MSCs (BM-MSCs) were cryopreserved in two cryoprotectants: the defined serum- and xeno-free STEM-CELLBANKER™ (CB) and 10 % dimethyl sulfoxide (DMSO) in a xeno-free serum replacement cell culture medium and compared to non-cryopreserved MSCs. MSCs cryopreserved in CB or DMSO had similar morphology and surface marker expression compared to their respective non-cryopreserved MSC. Ad-MSCs and BM-MSC in both cryoprotectant media exhibited reduced mean fluorescence intensity (MFI) for CD105, BM-MSCs for CD73 and Ad-MSC increased MFI for HLA class I compared to non-cryopreserved MSCs. Population doubling time of CB cryopreserved and non-cryopreserved Ad-MSCs was similar (38.1 ± 13.6 and 36.8 ± 12.1 h), but somewhat higher when cryopreserved in DMSO (42.2 ± 10.8 h). BM-MSCs had higher population doubling time (CB 47.7 ± 11.4 and DMSO 62.3 ± 32.9 h respectively, p < 0.05) compared to Ad-MSCs. The viability of Ad-MSCs was significantly higher after cryopreservation in CB compared to DMSO (90.4 ± 4.5 % vs. 79.9 ± 3.8 % respectively). Ad-MSCs and BM-MSCs retained their mesodermal differentiation potential when cryopreserved in both cryoprotectants. The characteristics of Ad-MSCs post-thawing are better preserved by CB than by DMSO in serum- and xeno-free medium. Furthermore, Ad-MSCs and BM-MSCs are differently affected by the cryoprotectants, which may have implications for cell therapy.

Citing Articles

Automated Manufacturing Processes and Platforms for Large-scale Production of Clinical-grade Mesenchymal Stem/ Stromal Cells.

Strecanska M, Sekelova T, Smolinska V, Kuniakova M, Nicodemou A Stem Cell Rev Rep. 2024; 21(2):372-389.

PMID: 39546186 PMC: 11872983. DOI: 10.1007/s12015-024-10812-5.


Comparative Analysis of Serum and Serum-Free Medium Cultured Mesenchymal Stromal Cells for Cartilage Repair.

Kang M, Yang Y, Zhang H, Zhang Y, Wu Y, Denslin V Int J Mol Sci. 2024; 25(19).

PMID: 39408956 PMC: 11476526. DOI: 10.3390/ijms251910627.


Exploring the Potential Effects of Cryopreservation on the Biological Characteristics and Cardiomyogenic Differentiation of Rat Adipose-Derived Mesenchymal Stem Cells.

Farag A, Ngeun S, Kaneda M, Aboubakr M, Elhaieg A, Hendawy H Int J Mol Sci. 2024; 25(18).

PMID: 39337396 PMC: 11432599. DOI: 10.3390/ijms25189908.


Harmonised culture procedures minimise but do not eliminate mesenchymal stromal cell donor and tissue variability in a decentralised multicentre manufacturing approach.

Calcat-I-Cervera S, Rendra E, Scaccia E, Amadeo F, Hanson V, Wilm B Stem Cell Res Ther. 2023; 14(1):120.

PMID: 37143116 PMC: 10161493. DOI: 10.1186/s13287-023-03352-1.


Xeno-free protocol for GMP-compliant manufacturing of human fetal pancreas-derived mesenchymal stem cells.

Jabbarpour Z, Aghayan S, Arjmand B, Fallahzadeh K, Alavi-Moghadam S, Larijani B Stem Cell Res Ther. 2022; 13(1):268.

PMID: 35729640 PMC: 9210668. DOI: 10.1186/s13287-022-02946-5.